难治性精神分裂症的非氯氮平干预:系统综述与Meta分析
该系统综述与Meta分析纳入78项研究(其中68项进入Meta分析,共3241例患者),评估非氯氮平干预对难治性精神分裂症阳性、阴性和总症状的疗效。多种增效策略(甘氨酸调节位点激动剂、非侵入性刺激、心理治疗、抗抑郁药增效)在小样本研究中显示获益,但均未达到可常规推荐替代氯氮平的证据阈值。
要点
- 高剂量抗精神病药未改善任何症状域。
- 甘氨酸调节位点激动剂改善阳性、阴性及总症状,证据等级低至极低。
- 非侵入性刺激与心理治疗对阳性症状有中等获益,证据等级低。
核心结论
- 多种增效策略在小样本研究中显示获益,但无干预达到可常规推荐替代氯氮平的证据阈值。
研究设计与样本
- 系统综述与Meta分析,检索PsycInfo、PubMed和EMBASE至2023年7月,方案注册于PROSPERO(ID: CRD42023418053)。
- 纳入78项研究,其中68项进入Meta分析,共3241例患者,采用随机效应模型合并效应量(Hedges' g)。
主要发现
- 高剂量抗精神病药(7项研究,467例)未改善任何症状域。
- 甘氨酸调节位点激动剂增效(9项研究,187例)改善阳性症状(g = -0.56 [-0.81, -0.31],GRADE低)、阴性症状(g = -1.18 [-1.49, -0.87],GRADE低)和总症状(g = -1.17 [-1.75, -0.59],GRADE极低)。
- 非侵入性刺激(26项研究,893例)对阳性症状有中等获益(g = -0.42 [-0.65, -0.18],GRADE低)。
- 心理治疗(10项研究,565例)对阳性症状有中等改善(g = -0.56 [-1.01, -0.10],GRADE低)。
- 抗抑郁药增效(3项研究,187例)改善阴性症状(g = -0.74 [-1.46, -0.02],GRADE极低)和总症状(g = -0.69 [-1.00, -0.38],GRADE低)。
关键数值与推荐
- 高剂量抗精神病药未改善任何症状域(7项研究,467例)。
- 甘氨酸调节位点激动剂改善阳性、阴性及总症状,GRADE评级低至极低(9项研究,187例)。
- 非侵入性刺激对阳性症状中度获益,GRADE低(26项研究,893例)。
- 心理治疗对阳性症状中度改善,GRADE低(10项研究,565例)。
- 抗抑郁药增效改善阴性及总症状,GRADE极低至低(3项研究,187例)。
临床怎么用
- 当氯氮平治疗不可行时,可考虑甘氨酸调节位点激动剂、非侵入性刺激、心理治疗或抗抑郁药增效,但需告知证据等级低且样本量小。
- 高剂量抗精神病药不推荐用于难治性精神分裂症的症状改善。
局限性
- 样本量小,非侵入性刺激研究存在明显发表偏倚。
- 多数干预的GRADE证据等级为低或极低,需高质量试验以给出明确推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Clozapine is the only licensed pharmacotherapy for treatment resistant schizophrenia (TRS), but in some cases is not a suitable treatment option. A review of the efficacy of non-clozapine interventions in TRS may help inform clinical decision making when clozapine treatment is not feasible. STUDY DESIGN: A systematic review and meta-analysis was performed investigating the efficacy of non-clozapine augmentation of antipsychotic treatment in TRS on positive, negative, and total symptoms. The review protocol is registered at PROSPERO (ID: CRD42023418053). PsycInfo, PubMed and EMBASE were searched up until July 2023. Cochrane Risk of Bias tool (v2) was used to assess study quality. Data were pooled using a random-effects model for each class of intervention to give an estimate of effect size (Hedges' g). RESULTS: 78 studies were included, of which 68 were included in the meta-analysis, comprising 3241 patients. High-dose antipsychotics (7 studies, 467 participants) did not improve any symptom domain. Augmentation of antipsychotics with glycine modulatory site agonists (9 studies, 187 participants) improved positive (g = -0.56 [-0.81, -0.31], GRADE rating Low), negative (g = -1.18 [-1.49, -0.87], GRADE rating Low) and total (g = -1.17 [-1.75, -0.59], GRADE rating Very Low) symptoms. Non-invasive stimulation (26 studies, 893 participants) moderately benefited positive symptoms (g = -0.42 [-0.65, -0.18], GRADE rating Low). Psychotherapy (10 studies, 565 participants) moderately improved positive symptoms (g = -0.56 [-1.01, -0.10], GRADE rating Low). Augmentation with antidepressants (3 studies, 187 participants) improved negative (g = -0.74 [-1.46, -0.02], GRADE rating Very Low) and total (g = -0.69 [-1.00, -0.38], GRADE rating Low) symptoms. Sample sizes were small, and publication bias was apparent for non-invasive stimulation studies. CONCLUSIONS: Several augmentation strategies, including pharmacotherapy, non-invasive stimulation, and psychotherapy demonstrated benefit in small studies, however no intervention reached the threshold of evidence to be routinely recommended as a viable alternative to clozapine. High-quality trials are needed for definitive recommendations.
引用
- Carr R, Cannon A, Finelli V, et al. Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis. Mol Psychiatry. 2025. PMID: 41044402. doi:10.1038/s41380-025-03255-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。